Business
Paysign, Inc. Reports Second-Quarter 2021 Financial Results
Second-quarter total loads and total gross dollar load volume increased 13.1% and 34.7% year-over-year, respectively Second-quarter purchase transactions and
About this update from Paysign, Inc.
[{"type":"text","content":"\n\nSecond-quarter total loads and total gross dollar load volume increased 13.1% and 34.7% year-over-year, respectively\n\n\nSecond-quarter purchase transactions and purchase dollar volume increased 19.1% and 44.5% year-over-year, respectively\n\n\nSecond-quarter total revenues of $6.7 million, a year-over-year increase of $0.2 million or 3.2%\n\n\nSecond-quarter plasma revenue of $5.9 million, a year-over-year increase of $1.4 million or 30.1%\n\n\nSecond-quarter net loss of $0.9 million, or diluted earnings per share (EPS) of ($0.02)\n\n\nSecond-quarter adjusted EBITDA of $0.2 million, or diluted adjusted EBITDA per share of $0.00 \n\n\n HENDERSON, Nev.--(BUSINESS WIRE)--\nPaysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, digital banking services and integrated payment processing, today reported financial results for the second quarter of 2021.\n\n“We are pleased to report a sequential improvement in our revenues and operating results for the quarter. Throughout the quarter we saw month-over-month improvements in our financial results as pandemic-related stimulus began to phase out, thus providing an incentive for individuals to supplement their income by donating plasma. This trend has continued in July despite the recent U.S. Customs and Border Protection decision affecting Mexican citizens’ ability to receive compensation for donating plasma, which only impacted revenue on about 7% of our plasma centers,” said Mark Newcomer, Paysign CEO. “We continue to focus on diversifying our business and investing for sustained long-term growth. With the renewal of a major pharmaceutical hub customer and their copay programs and the addition of five new pharmaceutical copay programs that are expected to launch between now and the end of 2021, we are excited to continue to advance our capabilities and value in the patient affordability space.”\n\n2021 Outlook\n\n“While the second quarter continued to be impacted by COVID-19 and government stimulus measures as expected, we did see improving trends as we moved through the quarter. Preliminary indications are that the improving trends will continue as long as the U.S. does not enter widespread lockdown conditions and the government does not provide additional stimulus checks to individuals. More importantly, we continue to believe that our business will benefit in ...